Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL-1R7) Ready for Development for the Treatment of the Cytokine-Release-Syndrome in Late-stage Covid-19

b3cnewswireMay 20, 2021

Tag: anti-IL-1R7 , the Cytokine-Release-Syndrome , COVID-19

PharmaSources Customer Service